Andersson-Rusch, Clara
Liu, Bin
Quist-Løkken, Ingrid
Upton, Paul D.
Olsen, Oddrun Elise
Hella, Hanne
Yang, Xudong
Tong, Zhen
Morrell, Nicholas W.
Holien, Toril
Li, Wei
Funding for this research was provided by:
British Heart Foundation (PG/12/54/29734, RG/19/3/34265, PG/12/54/29734, RG/19/3/34265, PG/12/54/29734, RG/19/3/34265)
the Liaison Committee for education, research, and innovation in Central Norway
the Joint Research Committee between St. Olav’s Hospital and Faculty of Medicine and Health Sciences, NTNU
Article History
Received: 11 November 2022
Accepted: 12 April 2023
First Online: 24 April 2023
Competing interests
: W.L. and P.D.U. are co-founders and scientific advisors to Morphogen-IX. N.W.M is a founder and CEO of Morphogen-IX. Other authors declare no competing interest.